GVAG
BBIO icon

Great Valley Advisor Group’s BridgeBio Pharma BBIO Stock Holding History

Great Valley Advisor Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+2,700
New +$189K ﹤0.01% 993
2021
Q4 		– Sell
-6,000
Closed -$281K – 600
2021
Q3 		$281K Hold
6,000
– – 0.02% 480
2021
Q2 		$366K Buy
+6,000
New +$343K 0.03% 413

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Great Valley Advisor Group's BBIO Position: Q2 2026 in Review

Great Valley Advisor Group opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 2,700 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #993 among its holdings. This is a return to the name: Great Valley Advisor Group previously reported a position in BBIO as recently as Q3 2021.

Great Valley Advisor Group first reported a position in BBIO in Q2 2021 and has held it in 3 quarters since. The position peaked at $366K in Q2 2021. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Great Valley Advisor Group held 2,700 shares of BridgeBio Pharma worth $201K as of Q2 2026.
  • BridgeBio Pharma was a new Great Valley Advisor Group position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q2 2026, its #993 holding.
  • Great Valley Advisor Group first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 3 quarters since.
  • Great Valley Advisor Group's BridgeBio Pharma position peaked at $366K in Q2 2021.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.